Le Lézard
Classified in: Health, Science and technology
Subjects: AVO, CPG

BC PharmaCare Expands Use of Biosimilar Medicines

First Province to Implement Large-Scale Biologic Switching Program

TORONTO, May 27, 2019 /CNW/ - Biosimilars Canada, a national association representing Canada's biosimilar medicines industry, today congratulated the Government of British Columbia for announcing a program in which patients taking originator biologic drugs will be "switched" or transitioned by their clinicians to a biosimilar biologic drug within a six-month period.

Biologic medicines have revolutionized the treatment and prevention of many disabling and life-threatening diseases over the past 50 years, but they are also very expensive and are a significant driver of increasing prescription drug costs. Just 1.7 per cent of Canadian prescriptions were filled with biologic drugs in 2018, yet the cost of these prescriptions represented 29.9 per cent of Canada's total prescription drug costs that year.

Public and employer-sponsored benefit plans want to provide patients with access to innovative new medicines. Biosimilar medicines present an important way to manage costs while also supporting positive patient outcomes.

"Biosimilar medicines have an important role in supporting health care sustainability and patient care, and Biosimilars Canada congratulates the Government of British Columbia for its Canadian and North American leadership in promoting and expanding the use of biosimilar medicines," said Michel Robidoux, Chair of Biosimilars Canada and President and General Manager of Sandoz Canada.

While the use of biosimilar medicines has been well-established in Europe with more than 700 million patient days of use over the past decade, the uptake of these medicines in Canada for chronic treatments has been much slower as public and private payers have not actively implemented policy levers to support their use beyond naïve or new patients. Canadian payers are now beginning to recognize that enhanced policies are needed to fully realize the value of biosimilar medicines.

"Switching or transitioning patients from original biologic treatments to their corresponding biosimilar medicines is the responsible choice for those who manage drug budgets, and will help to ensure patient access to essential treatments for years to come," said Jim Keon, President of Biosimilars Canada.

The evidence supporting such a policy is clear. By the end of 2017 there were 90 studies involving the "switching" or transitioning of 14,255 unique patients that provide real world evidence confirming the safety and efficacy of this practice. The BC PharmaCare announcement is also consistent with Health Canada's recommendation that such a decision should be made by the treating physician in consultation with the patient and taking into account available clinical evidence and any policies of the relevant jurisdiction.

Full details of the BC biosimilars initiative are available at: https://news.gov.bc.ca/releases/2019HLTH0080-001072

About Biosimilar Medicines
A biosimilar biologic drug, or biosimilar, is a drug demonstrated to be highly similar to a biologic drug that was already authorized for sale.1 Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them.2 Health Canada's rigorous standards for authorization mean that patients and health care providers can have the same confidence in the quality, safety and efficacy of a biosimilar as any other biologic drug.3

About Biosimilars Canada
Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. Its member companies are at the forefront of the global development and marketing of biosimilar medicines. Biosimilar medicines are approved by Health Canada as being as safe and efficacious as their reference biologic drugs, and are developed to the same quality standards. Biosimilar medicines present a significant opportunity to embrace cutting-edge therapies while addressing the cost-effectiveness demands on healthcare systems in Canada. Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association. Visit us at www.biosimilarscanada.ca.



Source: Health Canada. https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/fact-sheet-biosimilars.html






SOURCE Biosimilars Canada

These press releases may also interest you

at 09:00
mobileiGo.com, a leading online retailer of cell phone pouches and cases, mobile accessories and portable electronics, is proud to announce that they now offer a large selection of Reiko Wireless phone pouches, phone cases, chargers and other...

at 05:00
The new restaurant concept at Intu's Lakeside, harnesses the latest technology to offer a counter-less restaurant environment with 100% kiosk and app ordering, giving customers the best possible user experience. The founders' vision is for Chiktopia...

at 05:00
Surging demand for the iPhone 11 exceeds initial projections as forecasters expect up to 75 million units to sell by year's end, which means millions will soon be selling their old phones to help offset costs. Flipsy.com compared phone selling...

at 02:00
Chronic kidney disease affects 1 out of 10 people worldwide and is steadily increasing. When it reaches end-stage renal disease and endangers the lives of patients, dialysis or transplantation is required. Renal transplantation is the treatment of...

20 sep 2019
SymbioCellTech, LLC , a biotechnology company in Salt Lake City pioneering stem cell therapy for diabetes and associated auto-immune disorders and microvascular conditions, today announced the online journal PLOS ONE published interim data...

20 sep 2019
The Think Global Forum unveils a brand-new identity today, ahead of the launch of the Think Global Awards. The newly revealed identity reflects the purpose of the global forum, embodying a new visual language while retaining the brand position and...

News published on 27 may 2019 at 14:51 and distributed by: